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Accelerated radiotherapy prevent local relapse in molecular unfavourable breast cancer?
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Introduction. Molecular classiﬁcation is at present a useful tool to predict clinical outcome in breast cancer. Triple negative and
Her-2+ groups had worse survival and reduced local control after radiotherapy in patients treated by conventional fractionation,
probably through increased repopulation during the radiotherapy course.
Objective. The aim of the present study is whether accelerated hypofractionation breast irradiation can increase local control in
those bad prognosis molecular classiﬁed tumours.
Methods and materials. From January 2008 to December 2011, 399 patients with inﬁltrating breast carcinomas treated with con-
servatively surgery, were prospectively included. Mean age: 55.2, median: 54 (range 24–88 years old), 72.4% menopausal. DCI
(88.7%), cT1 (58.64%), cN0 (76.2%), and RE+ 81.2% and RP+ 87.9%. Her-2/neu+ (19.8%). Four patient groups were deﬁned by receptor
status: Group 1: Luminal A 121 (30.3%), Group 2: Luminal B 206 (51.6%), Group 3: Her-2+ 24 (6%), and Group 4: Triple N 48 (12%).
255 patients were initially referred to surgery and 144 received neoadjuvant treatment due to locally advanced disease. All were
treated by accelerated hypofractionation on the tumoral bed by a 2.35Gy/frx scheme. Those with negative margins received 47Gy
in 20 frx, those at moderate risk 58.75Gy in 25 frx and most of those with higher risk (very close or affected margins) 63.45Gy in
27 frx. Treatment acceleration allows a planned total treatment time of 28, 35 or 37 days respectively.
Results. After a mean follow-up: 30.85±13.45, median: 31 months (range 6–66) the 4 years ipsilateral tumour control rate was
95.51±0.02%. For those patients initially referred to surgery no differences were found in local control regarding molecular
subtypes: 93% vs 92.3%, p=0.441. Patients with locally advanced tumours initially treated with neoadjuvant chemotherapy high
risk subtypes did worse (89.4%) than luminal cases (98.2%) p=0.054.
Conclusion. Accelerated hypofractionated radiotherapy seems to be useful though preventing tumour repopulation for bad prog-
nosis molecular subtypes in early tumours. Longer follow-up will be needed to conﬁrm these encouraging results.
http://dx.doi.org/10.1016/j.rpor.2013.03.717
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Introduction. Axillary dissection is the standard treatment in patients with breast cancer and positive sentinel lymph node.
According to the literature in 40–70% of the lymphadenectomies, the sentinel node was the only nodal metástasis, implying
potential complications due to the intervention. Several groups have developed models to predict the likelihood of non-sentinel
node involvement in patients with positive sentinel biopsy.
Objectives. To determine the area under the ROC curve and predictive efﬁciency of the Memorial Sloan-Kettering Cancer Center,
Stanford, Tenon and Cambridge models in patients of The General Hospital of Catalunya.
Methods. We studied retrospectively the performance of the models in 48 patients at our hospital from October 2002 to December
2012, who met the following criteria: invasive primary breast cancer without clinical nodal affection, positive sentinel biopsy
and lack of neoadjuvant treatment before sentinel node biopsy or lymph node dissection.
Results. According to the literature, we observed that 62.5% of GC (+) and 76.5% of GC micrometastasis (+) had negative lym-
phadenectomy. The area under the ROC curve for the MSKCC, Stanford, Tenon and Cambridge models was 0.609 (IC95%
0.449–0.769), 0.642 (IC95% 0.479–0.805), 0.539 (IC95% 0.375–0.703) and 0.560 (IC95% 0.395–0.725) respectively. The cut-off points
for higher efﬁcient diagnostic of the MSKCC, Stanford, Cambridge and Tenon models were in a predicted probability of 12.5%
(sensitivity 94.4% and speciﬁcity 33.3%), 12.2% (sensitivity 94.4% and speciﬁcity 23.3%), 16.8% (sensitivity 94.4% and speciﬁcity
20%) and Tenon score 2.75 (sensitivity 94.4% and speciﬁcity 30%) respectively.
Conclusions. We did not observe any area under the ROC curve greater than 0.70, therefore these models should not be applied to
our population. Further research is needed to conﬁrm that the omission of lymphadenectomy is safe and if the optimization of
the cut-off points could reduce the false positive results when counseling patients about their risk of additional nodal disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.718
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One of themost important prognostic indicators in patientswith breast cancer is axillary lymphnode status. Sentinel lymphnode
(SLN) biopsy has emerged as a potential alternative to routine axillary dissection in clinically node-negative early breast cancer.
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The adjuvant treatments dependent on ﬁndings from lumpectomy and SLN specimens. The aim of this study is to determine
the prevalence of addiction disease in patient with micrometastatic sentinel node and assess potential predictors factors.
Materials and methods. Retrospective analysis of 1213 patients in the University Hospital of Vigo and Pontevedra with breast
cancer in stage T1–T2 selecting those with micrometastases in the sentinel lymph node biopsy (SLNB), between January 2007
and December 2011. Excluding subjects with chemotherapy neoadjuvant, surgery and/or radiotherapy and no migration of the
radiotracer.
Results. We revised 1213 SLNB: 254 (20.9%) macrometastases followed by ALND (pN1a1b2), 101 micrometastases (8.32%), 38 (3.1%)
isolated cells (pN0 (i+)), 820 (67.6%) negative (pN0(i−)). Micrometastases (101) in SLNB: 25 (24.7%) patients were not performed
ALND, of these 13 received radiotherapy axillaries chains. All without relapse of disease and free of side effects from RT. 76
(75.24%) was performed ALND: 11(21%) with macrometastases, 2 (8%) micrometastases. 4 (3%) isolated tumor cells and 63 (68%)
non metastases. Mean follow-up 32 months (range 5–59). 76.3% Grades 2–3. Her2 negative 63.3%. Invasive ductal carcinoma and
hormone receptor positive majority. Received hormone therapy 92% and chemotherapy 73.6%. 2 patients developed metastases,
4 deaths, 1 per progression.
Conclusion. In our series, the rate of additional axillary disease in patients with micrometastases in SLNB is low. However 14% have
disease>2mm. A selected subgroup of patients N1mi, could be avoided ALND without deteriorating its forecast. The decision of
ALND should be individualized considering multiple factors. We did not ﬁnd association between additional disease and size,
grade, Ki67/Her2 status or histological type.
http://dx.doi.org/10.1016/j.rpor.2013.03.719
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Objective. Evaluate toxicity, aesthetic result and outcome in the ﬁrst 294 breast cancer patients (pts) treated with hypofractionated
radiotherapy (HFRT) scheme at 2 years of follow up.
Material and methods. Clinical records of 294 breast cancer pts receiving postoperative HPRT after conservative surgery pts had
been evaluated. Age: mean 57.26 years (range 30–80). Tumor location: 54.08% (158) of the pts on the right breast and 45.92%
(136) on the left. Surgical treatment: lumpectomy+sentinel lymph node technique (181 pts, 61.56%), quandrantectomy+axillary
dissection (60 pts, 20.40%), and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI (94.89%). Tumor size: 1.39 cm
(range 0.4–5.8). Histological grade: GI 29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) with positive margins.
Hormone receptors: (−) in 6.46%. HER-2: (−) in 11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: mean 12.5 (range
1–24). Positive 1.02 (range 0–2). Stage: I 70.06%, II 27.55%, and III 2.39%. HFRT schedule: Breast: 40.5Gy in 15 fractions of 2.7Gy.
Boost: 103 pts (35.03%) received no boost, 191 (64.97%) received 13.5Gy/5 fr. Adjuvant chemotherapy: 52.38%. Hormone therapy:
58.87%. Follow-up schedule: weekly based during HPRT, 1 month after its completion and, later, every three months.
Results. 77 pts (26.19%) developed radiodermitis. 64 Grade I and 13 Grade II. Mean dose of radiodermitis appearance: 34.92Gy
(range 13.5–46.5). At 6 months, 17 pts (5.78%) had a slight residual hyperpigmentation in the treated area. At 1 year only 5 pts
(1.70%) presented it. At 2 years 2 local relapse have occurred and all remaining pts had a normal-looking skin.
Conclusions. Toxicity and local control of HFRT are equivalent to that obtained with conventional fractionation. Besides, HFRT
reduces total time of treatment and a decrease in the waiting list is achieved.
http://dx.doi.org/10.1016/j.rpor.2013.03.720
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Introduction. If we review literature, radiation-related complication rates seem to be higher among women undergoing
expander/implant reconstruction, irrespective of when RT is given in relation to surgery. The late results of the complex tissue
changes induced by RT are capsular contracture, impaired skin healing, implant rupture, malpositioning or extrusion. However,
not all studies indicate poor cosmetic/aesthetic outcomes or satisfaction in women who undergo immediate reconstruction
followed by RT. In general, if there is indication of administering adjuvant radiotherapy, delayed reconstruction is preferred. But
in some cases this is impossible, either because the indication for postoperative radiation therapy arises after surgery, either by
explicit request of the patient.
Objective. To show our experience in treating patients after breast reconstruction with a breast expander.
